The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinsons disease, levodopa treatment response, and complications

Pharmacogenetics and Genomics

Volumn 18, Issue 9, 2008, Pages 815-821

  Bialecka, Monika ^a   Kurzawski, Mateusz ^a   Klodowska Duda, Gabriela ^b   Opala, Grzegorz ^b   Tan, Eng King ^c   Drozdzik, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Catechol O methyltransferase; Genetic polymorphism; Haplotypes; Parkinsons disease; Single nucleotide polymorphisms

Indexed keywords

CATECHOL METHYLTRANSFERASE; LEVODOPA; ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DYSKINESIA; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HAPLOTYPES; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 53049101630     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328306c2f2     Document Type: Article

References (28)

1. Shibata N, Kobayashi M. The role for oxidative stress in neurodegenerative diseases. Brain Nerve 2008; 60:157-170.
2. Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, Sun L, et al. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 2007; 120:857-863.
3. Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat 2007; 28:641-653.
4. Agundez JA, Jimenez-Jimenez FJ, Luengo A, Bernal ML, Molina JA, Ayuso L, et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995; 57:291-298.
5. Agundez JA, Jimenez-Jimenez FJ, Luengo A, Molina JA, Orti-Pareja M, Vazquez A, et al. Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease. Neurology 1998; 5:1587-1592.
6. Tan EK, Jankovic J. Genetic testing in Parkinson disease: promises and pitfalls. Arch Neurol 2006; 63:1232-1237.
7. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44:595-600.
8. Hicks AA, Petursson H, Jonsson T, Stefansson H, Johannsdottir HS, Sainz J, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 2002; 52:549-555.
9. Oliveira SA, Li YJ, Noureddine MA, Zuchner S, Qin X, Pericak-Vance MA, et al. Identification of risk and age-onset genes on chromosome 1p in Parkinson disease. Am J Hum Genet 2005; 77:252-264.
10. Zhu BT. Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 2002; 3:321-349.
11. Białecka M, Drozdzik M, Honczarenko K, Gawrońska-Szklarz B, Stankiewicz J, Da̧browska E, et al. Catechol-O-methyltransferase (COMT) and monoamine oxidase B (MAOB) genes and susceptibility to sporadic Parkinson's disease in a Polish population. Eur Neurol 2005; 53:68-73.
12. Jellinger K, Kienzl E, Rumpelmaier G, Riederer P, Paulus W, Stachelberger H, et al. Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 1993; 59:1168-1171.
13. Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, Franko MW, et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 2008; 115:193-203.
14. Ricera-Caliman L, Reilly DK. Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance. Clin Pharmacol Ther 1984; 35:804-809.
15. Lee MS, Kim HS, Cho EK, Lim JH, Rinne JO. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Neurology 2002; 58:564-567.
16. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, et al. Kinetics of human soluble and membrane-bound catechol-O- methyltransferase: a revised mechanism and description of the termolabile variant of the enzyme. Biochemistry 1995; 34:4202-4210.
17. Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F, et al. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease. Neurosci Lett 1997; 221:202-204.
18. Xie T, Ho SL, Li SW, Ma OC. G/A1947 polymorphism in catechol-O- methyltransferase (COMT) gene in Parkinson's disease. Mov Disord 1997; 12:426-427.
19. Yoritaka A, Hattori N, Yoshino H, Mizuno Y. Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in Japan. J Neural Transm 1997; 104:1313-1317.
20. McLeod HL, Syvanen AC, Githang A, Indalo A, Ismail D, Dewar K, et al. Ethnic differences in catechol-O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics 1998; 8:195-199.
21. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006; 314:1930-1933.
22. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005; 14:135-143.
23. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A silent polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525-528.
24. Daniel SE, Lees AJ. Parkinson's disease society brain bank, London: overview and research. J Neural Transm Suppl 1993; 39:165-172.
25. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17:427-442.
26. Wu RM, Cheng CW, Chen KH, Lu SL, Shan DE, Ho YF, et al. The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese. Neurology 2002; 56:375-382.
27. Eerola J, Launes J, Hellstrom O, Tienari PJ. Apolipoprotein E (APOE), PARKIN and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson's disease in Finland. Neurosci Lett 2002; 330:296-298.
28. Białecka M, Drozdzik M, Kłodowska-Duda G, Honczarenko K, Gawrońska-Szklarz B, Opala G, et al. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphism on levodopa therapy in patients with sporadic Parkinson disease. Acta Neurol Scand 2004; 110:260-266.